{"id":"oxy-apap","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"20-30","effect":"Constipation"},{"rate":"10-20","effect":"Dizziness"},{"rate":"15-25","effect":"Drowsiness"},{"rate":"10-15","effect":"Vomiting"},{"rate":"5-10","effect":"Pruritus"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxycodone is a semi-synthetic opioid that binds to mu opioid receptors in the central nervous system to reduce pain perception and transmission. Acetaminophen works through distinct mechanisms including inhibition of prostaglandin synthesis and modulation of serotonergic and noradrenergic pathways. The combination provides synergistic analgesia, allowing lower opioid doses while maintaining efficacy and potentially reducing opioid-related adverse effects.","oneSentence":"OXY/APAP combines oxycodone (an opioid analgesic) with acetaminophen (a non-opioid analgesic) to provide enhanced pain relief through dual mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:12.187Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute pain"}]},"trialDetails":[{"nctId":"NCT00315445","phase":"PHASE3","title":"The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"1997-12","conditions":"Back Pain","enrollment":134}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"SUBSTANCE USE DISORDER"},{"count":11,"reaction":"DEPENDENCE"},{"count":10,"reaction":"OVERDOSE"},{"count":9,"reaction":"DRUG DEPENDENCE"},{"count":8,"reaction":"ECONOMIC PROBLEM"},{"count":6,"reaction":"DEATH"},{"count":5,"reaction":"CARDIAC ARREST"},{"count":5,"reaction":"PERSONAL RELATIONSHIP ISSUE"},{"count":4,"reaction":"ANXIETY"},{"count":4,"reaction":"COMPLETED SUICIDE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OXY/APAP","genericName":"OXY/APAP","companyName":"Purdue Pharma LP","companyId":"purdue-pharma-lp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OXY/APAP combines oxycodone (an opioid analgesic) with acetaminophen (a non-opioid analgesic) to provide enhanced pain relief through dual mechanisms. Used for Moderate to severe acute pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}